Rivian Automotive, Inc. vs Smith & Nephew plc — how do they compare? Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B), while Smith & Nephew plc trades at $27.08 (market cap $11.10B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Smith & Nephew plc for 120 Days on average.
| RIVN | SNN | |
|---|---|---|
Market Cap | $20.75B | $11.10B |
Volume | 26,144,654 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $37.17 |
52-Week Low | $12.50 | $26.42 |
Typical Hold Time | 61 Days | 120 Days |
Enterprise Value | $20.79B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.03, down 2.16% amid bearish technical signals despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving revenue trends and cash flow reduction. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show selling pressure with RSI near oversold levels.
Rivian presents a high-risk growth opportunity with significant operational improvements but persistent losses. The R2 SUV rollout and autonomy technology development offer long-term potential, while near-term challenges include cash burn and competitive EV market pressures. Investors should weigh improving fundamentals against substantial execution risks in a capital-intensive industry.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →